{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-169191","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2024-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.224556+00:00","generated_at":"2026-06-01T01:45:55.892197+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Taysha Gene Therapies prices $75M public offering of common stock and pre-funded warrants","bullets":["Gross proceeds ~$75M; 14,361,113 shares at $2.25 each and 18,972,221 pre-funded warrants at $2.249 each.","Net proceeds ~$70M (~$80.6M if underwriters exercise option for 5M additional shares).","Cash runway extended into Q4 2026; proceeds fund operating expenses and capex.","Pre-funded warrants exercisable at $0.001 per share with 4.99%/9.99% ownership caps.","Jefferies, Goldman Sachs, and Cantor act as book-running managers; closing expected June 27, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-169191","json":"https://secwatch.observer/filing/0001193125-24-169191.json","markdown":"https://secwatch.observer/filing/0001193125-24-169191.md","text":"https://secwatch.observer/filing/0001193125-24-169191.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312524169191/0001193125-24-169191-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312524169191/d857341d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T01:45:55.892197+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}